Ling W, Shoptaw S, Goodman-Meza D. Subst Abuse Rehabil. 2019;10:69–78.
The authors of this paper have advised that Table 1 is incorrect. The authors advised that they had listed values for Cmax and Ctrough after a single dose of Brixadi (CAM2038) and not steady state, as it was provided for Sublocade. The new Table 1 reflects the Brixadi steady state concentrations for a more direct comparison with Sublocade.
Table 1.
Comparison of Long-Acting Formulations of Buprenorphine FDA-Approved for Treatment of Opioid Use Disorder
| Brand Name | Probuphine | Sublocade | Brixadi (US) or Buvidal (Europe/Australia) |
|---|---|---|---|
| Molecular name | RBP-6000 | CAM2038 | |
| Pharmaceutical | Previously Braeburn, currently Titan | Indivior | Braeburn Pharmaceuticals/Camurus |
| Indicated population | Stable transmucosal buprenorphine dose of 8 mg or less for three months or longer | Initiated transmucosal buprenorphine (8–24 mg) for a minimum of 7 days. | Initiation of treatment in patients not already receiving buprenorphine or switching from transmucosal buprenorphine |
| Route of administration | Subcutaneous implant | Subcutaenous injection | Subcutaenous injection |
| Duration of effect | 6 months | 1 month | 1 week or 1 month |
| Dosage | 320 mg (Four 80 mg implants) | 100 and 300 mg | 8, 16, 24 and 32 mg (weekly) or 64, 96 and 128 mg (monthly) |
| Long acting technology | Ethylene vinyl acetate (EVA) polymer | 18% (weight/weight) buprenorphine base in the ATRIGEL Delivery System | Prolonged release FluidCrystal injection depot technology |
| Location | Upper arm | Abdomen | Buttock, thigh, stomach (abdomen) or upper arm |
| FDA-approval | 2016 | 2017 | 2018 (tentative) |
| Plasma concentrations (ng/mL) | Cmax | Cmax | Cmax |
| 3.23 | 4.88 (100 mg) | Weekly 4.3–6.9 | |
| 10.12 (300 mg) | Monthly 4.0–11.1 | ||
| Ctrough | Ctrough | Ctrough | |
| 0.72 | 2.48 (100 mg) | Weekly 0.8–2.6 | |
| 5.01 (300 mg) | Monthly 1.3–2.1 | ||
| Provider burden | +++ | ++ | ++ |
| Live training program | Supervised injection | Supervised injection | |
| Procedural competency | Monthly injections | Weekly or monthly injections | |
| Special Handling Requirements | Requires implant procedure | Needs Refrigeration | No special requirements |
| Need for removal or replacement every 6 months | Injection only under skin around umbilicus |
The correct Table 1 is as follows: